Lexeo Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Lexeo Therapeutics Inc 's ROA in the second quarter of 2026?
Lexeo Therapeutics Inc recorded a cumulative net loss of $-87 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -29.08%.

However, within the Healthcare sector 472 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3811, from total ROA ranking in the first quarter of 2026 at 4657.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	205.34 %	99.19 %	95.89 %	-12.63 %	-3.97 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-87	-88	-100	-105	-114
Return On Assets (TTM)	-29.08 %	-41.72 %	-55.98 %	-72.05 %	-75.67 %
LXEO's Total Ranking	# 3811	# 4657	# 4209	# 4289	# 4338
Total Assets (TTM) in million	538	250	269	144	176
Seq. Total Assets Change	114.73 %	-6.82 %	86.79 %	-18.3 %	40.08 %
Seq. Net Income Change	-	-	-	-	-

LXEO's 5 Years Annual ROA >> Back to LXEO Management Effectiveness >> Compare LXEO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 55
Sector	# 473
Overall	# 3728

Return On Assets Statistics
High	Average	Low
-38.03 %	-55.73 %	-73.36 %
(Jun 30 2026)		(Jun 30 2025)

Financial Statements
Lexeo Therapeutics Inc 's Assets	$ 538 million	LXEO's Balance sheet
Lexeo Therapeutics Inc 's Income	$ -26 million	Quarterly LXEO's Income Statement
LXEO's Income by Division		See LXEO's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	FY	FY
Y / Y Total Assets Change	143.14 %	6.04 %	-	-	-
Total Assets in million	333	137	129	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-100	-98	-66	0	0
Annual Return On Assets	-29.97 %	-71.69 %	-51.33 %	-	-

LXEO's 5 Years Annual ROA >> Back to LXEO Management Effectiveness >> Compare LXEO ROA to its Competitors

More Return On Assets Ratios
LXEO's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LXEO's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LXEO's Competitors
Subscribers only: Roa for Lexeo Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for LXEO's Customers

You may also want to know
LXEO's Roi	LXEO's Inventory Turnover Ratio	LXEO's Growth Rates	LXEO's Dividend Comparisons
	LXEO's Profitability Ratios	LXEO's Asset Turnover Ratio	LXEO's Dividend Growth
LXEO's Roe	LXEO's Valuation Ratios	LXEO's Financial Strength Ratios	LXEO's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:42:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.